|
시장보고서
상품코드
2117037
비알코올성 지방간 질환 시장 : 약물 계열별, 투여 경로별, 유통 형태별, 연령층별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)Non-Alcoholic Fatty Liver Disease Market, By Drug Class, By Route of Administration, By Distribution, By Age Group, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033 |
||||||
비알코올성 지방간 질환(NAFLD) 시장 규모는 2025년에 34억 520만 달러로 평가되며, 2026년부터 2033년까지 CAGR 16.3%로 확대될 것으로 전망됩니다.
비알코올성 지방간 질환(NAFLD)의 치료에는 병적인 지방 축적, 염증, 대사 기능 장애에 대한 의약품 외에도 항산화제,지질강하제, 티아졸리딘디온 계열 약물, FXR 작용제, 비구아나이드 계열 약물, 항섬유화제 등 간섬유증에 대한 치료법도 포함됩니다. 대부분의 약물은 경구로 투여되지만, 인크레틴 계열 약물이나 병용요법을 포함한 주사제 치료법에 대한 수요가 증가하고 있습니다.
이상적인 접근 방식은 섬유화 진행 단계 및 관련 대사 이상에 따라 환자를 계층화하는 것입니다. 또한, 치료법 선택은 생검을 통한 확인 또는 비침습적 섬유화 진행 평가를 바탕으로 이루어지며, 단순히 지방 함량을 감소시키는 것뿐만 아니라 질병 경과를 개선한다는 증거가 필요하다는 점에 중점을 두고 있습니다. FDA에 따르면, MASLD는 미국 성인의 약 6%에 영향을 미치고 있으며, 시장에서는 적절한 치료법을 활용하여 환자를 보다 개별화된 방식으로 치료하는 방향으로 전환할 필요가 대두되고 있습니다.
비알코올성 지방간 질환(MASLD) 시장 - 시장 역학
섬유화 개선이 대사 위험 관리를 넘어선 치료로 이어집니다
임상 관리의 현재 동향은 단순한 체중 감소나 당뇨병, 이상지질혈증 등의 관련 질환뿐만 아니라 간 손상 그 자체의 치료로 전환되고 있습니다. 규제 환경은 현재 섬유화 및 지방간염의 해소를 목표로 하는 임상시험에 초점을 맞추고 있으며, 이는 질환 수정 치료제 시장의 상업적 성공을 위한 중요한 차별화 요소이자 전문의 처방의 중요성을 높이고 있습니다. 또한, 개발 기업은 조직학적 개선 또는 검증된 비침습적 개선을 제시하고 장기적인 안전성을 입증해야 하므로, 더 높은 수준의 근거가 요구되고 있습니다. FDA는 2025년 8월, MASLD 치료제로 세마글루티드를 승인했습니다. 이는 이 약물을 투여받은 피험자 중 63%에서 섬유화 진행이 관찰되지 않았고, MASLD가 해소된 것으로 확인되었기 때문입니다. 이 결과는 대상 집단에서 이후 진행된 일련의 임상시험과 섬유화 시장 내 경쟁에 큰 영향을 미쳤습니다.
비알코올성 지방간 질환 시장 - 시장 세분화 분석:
세계 비알코올성 지방간 질환 시장은 약물 분류, 투여 경로, 유통 형태, 연령대 및 지역에 따라 세분화되어 있습니다.
제시된 약물 분류별 세분화에서 섬유증에 대한 치료 옵션은 가장 유망한 전략적 위치를 차지하고 있으며, 그중에서도 질환 수정 요법이 명확히 드러난 미충족 의료 수요로 부상했습니다. 따라서, 질환의 특정 조직학적 병기를 표적으로 하여 진행을 억제하는 것으로 입증된 치료법은 가장 큰 차별화 잠재력을 지니고 있습니다. 반면, 항산화제, 지질 저하제, TZD 및 비구아나이드의 경우, 적응증이 질병 수정이라기보다는 산화 스트레스 해소와 밀접하게 관련되어 있기 때문에 적용 범위가 비교적 제한적입니다. FXR 작용제도 간 섬유증에 영향을 미치지만, 최근의 규제상의 우려로 인해 그 개발이 제한되고 있습니다. 섬유화를 표적으로 하는 치료법은, F2 또는 F3 단계 환자 917명을 대상으로 유효성을 확인한 Rezdiffra 임상시험의 결과, 그 개념이 널리 긍정적으로 평가됨에 따라 확립되었습니다. 임상시험을 통해 얻은 근거는 지역을 불문하고 일반적인 위치 설정 및 전문의의 인식을 형성하는 데 가장 중요한 역할을 하고 있습니다.
투여 경로에 관해서는, 투여 일정의 편의성에 더해 정기적인 주사에 비해 전반적인 복약 순응도가 용이하기 때문에 경구 투여가 명백히 우수합니다. Rezdiffra는 1일 1회 복용이며, 이는 섬유증의 적응증 전반에 걸쳐 1일 1회 치료의 가능성을 더욱 부각시키고 있습니다. 비경구 투여법은 더 높은 혈중 농도를 달성하고 인크레틴 효과를 활용하는 데 적합하지만, 투여 절차가 추가됩니다. 질환 수정 가능성을 지닌 GLP-1 조절제의 등장으로 인해, 투여 경로의 양분화는 재고가 요구되고 있습니다. 이 적응증에서 조직학적 개선을 넘어선 임상적 유효성을 입증하기 위한 세마글루타이드의 240주 임상시험은 2025년에 FDA의 승인을 받아야 합니다. 경구 치료는 비경구 치료에 비해 편의성 측면에서 우위를 유지할 것이지만, 비경구 치료는 질환 수정 효과를 활용함으로써 시장 내 입지를 강화할 가능성이 있습니다.
비알코올성 지방간 질환(NAFLD) 시장 - 지역별 인사이트
성숙한 의약품 시장, 간학 분야의 전문 지식, 그리고 규제 당국의 활동 덕분에 북미는 NAFLD 치료제의 중요한 상업적 기준지가 되었습니다. 미국에서는 전문의의 전문 지식과 대사 질환 치료 인프라가 융합되어 있어, 확립된 치료 경로 내에서 간 특이적 치료제의 도입을 촉진하고 있습니다. 또한, 2025년 미국에서 MASLD(간섬유증을 동반한 비알코올성 지방간 질환)에 대한 세마글루티드가 FDA 승인을 받은 것은 미국 시장 내 치료 옵션의 확대뿐만 아니라, 다른 섬유증을 표적으로 하는 약물과의 직접적인 비교 기준도 제공하고 있습니다. 섬유증은 미국에서 유병률이 높은 질환으로, FDA 추산에 따르면 1,490만 명의 미국인이 MASLD를 앓고 있는 것으로 알려져 있습니다. 북미는 제품 출시, 전문의의 채택, 그리고 상업적 성공 측면에서 앞으로도 중요한 영향력을 행사하는 지역으로 남을 것입니다.
유럽은 승인 획득 및 임상 증거 구축 양면에서 미국을 대체하는 규제 및 임상 개발의 거점으로 부상하고 있습니다. EMA는 2025년 6월에 ‘레즈디프라’에 조건부 승인을 부여했으며, 같은 해 8월에는 유럽집행위원회로부터 판매 승인을 받았습니다. 이는 유럽에서 이용 가능한 최초의 MASLD 치료제이며, 해당 규제 결정은 주요 임상시험에서 도출된 긍정적인 데이터를 바탕으로 이루어졌습니다. 이 임상시험에서 레즈디프라 100mg으로 치료받은 환자의 29%에서 섬유화 개선이 확인되었으며, 치료군에서는 MASLD의 악화가 관찰되지 않았습니다. 다만, 승인 과정에서 EMA는 보다 장기적인 증거의 제출을 요구했습니다. 이처럼 유럽은 상업적 및 임상적으로 큰 가치를 지닌 지역이지만, 국가 간 의료기술평가(HTA)의 차이가 각 치료법의 상대적 성공을 좌우하게 될 것입니다.
목차
제1장 비알코올성 지방간 질환 시장 개요
제2장 주요 요약
제3장 비알코올성 지방간 질환 주요 시장 동향
제4장 비알코올성 지방간 질환 산업 분석
제5장 비알코올성 지방간 질환 시장 : 높아지는 지정학적 긴장의 영향
제6장 비알코올성 지방간 질환 시장 구도
제7장 비알코올성 지방간 질환 시장 : 약물 계열별
제8장 비알코올성 지방간 질환 시장 : 투여 경로별
제9장 비알코올성 지방간 질환 시장 : 유통별
제10장 비알코올성 지방간 질환 시장 : 연령층별
제11장 비알코올성 지방간 질환 시장 : 지역별
제12장 주요 벤더 분석 : 비알코올성 지방간 질환 산업
제13장 AnalystView의 전방위 전망
KSM 26.08.26Non-Alcoholic Fatty Liver Disease Market size was valued at US$ 3,405.2 Million in 2025, expanding at a CAGR of 16.3% from 2026 to 2033.
Non-alcoholic fatty liver disease (NAFLD) encompasses pharmaceuticals for the treatment of pathological fat accumulation, inflammation, and metabolic dysfunction, as well as therapies for liver fibrosis, including antioxidants, lipid-lowering agents, thiazolidinediones, FXR agonists, biguanides, and antifibrotic agents. Most drugs are administered orally, and there is a need for injectable therapies, including incretin-based and combination approaches.
The ideal approach is to stratify patients according to the stage of fibrosis and the associated metabolic disorders. In addition, the choice of therapy is based on biopsy-proven or non-invasive assessment of fibrosis progression, with an emphasis on the need for evidence of disease modification rather than only fat content reduction. According to the FDA, MASLD affects about 6% of U.S. adults, determining the need for the market to shift to a more individualized approach to treating patients with appropriate therapies.
Non-Alcoholic Fatty Liver Disease Market- Market Dynamics
Fibrosis Modification Moves Treatment Beyond Metabolic Risk Control
The current trend in clinical management is shifting toward the treatment of liver damage, not only weight loss or related conditions such as diabetes or dyslipidemia. The regulatory environment now focuses on trials targeting the resolution of fibrosis and steatohepatitis, which is an important differentiator for commercial success in the market for disease-modifying agents, increasing the relevance of specialist prescribers. Additionally, a higher level of evidence is required since the developer should provide either histological or validated non-invasive improvement, and long-term safety should be demonstrated. The FDA approved semaglutide for the treatment of MASLD in August 2025, as among the participants who received the drug, there was a resolution of MASLD without progression of fibrosis noted in 63%. The findings significantly impacted the subsequent wave of clinical trials and competition in the fibrosis market in the studied population.
Non-Alcoholic Fatty Liver Disease Market- Segmentation Analysis:
The Global Non-Alcoholic Fatty Liver Disease Market is segmented on the basis of Drug Class, Route of Administration, Distribution, Age Group, and Region.
Within the given drug-class segmentation, treatment options for fibrosis possess the most promising strategic positioning, of which disease modification emerged as the clearly stated unmet medical need. Therefore, therapies that have been proven to reduce progression by targeting the specific histological stages of the disease possess the biggest differential potential. Meanwhile, antioxidants, lipid-lowering agents, TZDs, and biguanides have a more limited scope due to their target indications, which are closely linked to addressing oxidative stress rather than disease modification. Although FXR agonists also affect liver fibrosis, their development has been limited due to recent regulatory concerns. Fibrosis-targeted treatment modalities were established due to the large and positive readout for the concept following the Rezdiffra study, which enrolled 917 patients with F2 or F3 and confirmed efficacy. Evidence from clinical trials plays the biggest role in shaping the generic positioning and specialist perceptions across regions.
Regarding the route of administration, oral is clearly superior due to the convenience of the dosing schedule, as well as overall simpler compliance compared to regular injections. Rezdiffra is taken once per day, which further highlights the potential for once-daily treatment across the fibrosis indications. Parenteral approaches are suitable for achieving greater exposure and utilizing the incretin effect, but they involve additional administration steps. The split in the route of administration is being challenged due to the launch of GLP-1 modulators, which possess disease-modifying potential. Within the indication, semaglutide's 240-week trial to demonstrate clinical benefit beyond histological improvement now needs to be approved by the FDA in 2025. Orally administered therapy will maintain the convenience differential over parenteral treatments, but the latter can leverage disease modification to increase the positioning.
Non-Alcoholic Fatty Liver Disease Market- Geographical Insights
A mature pharmaceutical market, hepatology expertise, and regulatory activity make North America the key commercial reference center for NAFLD therapies. The United States affords a combination of specialist input and metabolic care infrastructure, facilitating the arrival of liver-specific therapeutics within an established care pathway. In addition, the FDA approval of semaglutide for MASLD in the United States in 2025 provides both therapy options for the U.S. market and a direct comparison for other fibrosis-targeting agents. Fibrosis is a prevalent condition within the United States, with the FDA estimating that 14.9 million Americans have MASLD. North America is likely to remain the region of key influence for product launches, specialty uptake, and commercial success.
Europe is emerging as an alternative regulatory and clinical-development hub to the United States, both for the purposes of securing approvals and building clinical evidence. The EMA granted conditional approval to Rezdiffra in June 2025, with marketing authorization granted by the European Commission in August of the same year. It is the first MASLD therapy available in Europe, with positive data from its pivotal trial informing the regulatory decision. Within the trial, treatment of patients with Rezdiffra at 100 mg demonstrated improvements in fibrosis for 29% of patients with no worsening of MASLD in the treatment group, although longer-term evidence was requested by the EMA during the approval process. As such, Europe represents a region of significant commercial and clinical value, although variations in health technology assessment between countries will dictate the relative success of different therapies.
Non-Alcoholic Fatty Liver Disease Market- Competitive Landscape:
Competition is now focused on greater proof of fibrosis improvement, metabolic benefit, route of administration convenience, and the capacity to target a substantial number of specialists compared to the legacy management of symptoms. Madrigal's resmetirom created a precedent for an oral and liver-directed approach, while Novo Nordisk's semaglutide's MASLD indication made the company's injectable platform more attractive. Development is also concentrated on obesity, diabetes, and liver disease mechanisms, allowing the companies to capitalize on infrastructure and physician relationships. Novo Nordisk employs 69,505 workers globally as of 2025, exemplifying the investment required to navigate the development, manufacturing, and regulatory approval processes across multiple regions. The competitive position within the industry is now based on metabolic disease platforms, established liver endpoints, and commercial reach.
Recent Developments:
In August 2025, Novo Nordisk's Wegovy (semaglutide) received FDA approval for the treatment of noncirrhotic MASH with moderate-to-advanced fibrosis, thereby expanding its therapeutic area to include liver disease and competing with resmetirom in the fibrosis-focused MASH treatment landscape.
In August 2025, the European Commission granted conditional marketing authorization to Madrigal Pharmaceuticals for Rezdiffra (resmetirom) for the treatment of noncirrhotic MASH and moderate-to-advanced fibrosis in adults, thereby bringing its liver-directed drug therapy to the European Union.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Madrigal Pharmaceuticals, Inc.
- Novo Nordisk A/S
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd. / 89bio
- Gilead Sciences, Inc.
- AbbVie Inc.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Inventiva S.A.
- AstraZeneca plc
- GSK plc
- Viking Therapeutics, Inc.
- Altimmune, Inc.
- Sagimet Biosciences Inc.
- Terns Pharmaceuticals, Inc.
- Galectin Therapeutics Inc.
- Galmed Pharmaceuticals Ltd.
- NGM Biopharmaceuticals, Inc.
- Bristol Myers Squibb
- Zydus Lifesciences Ltd.
- Others
GLOBALNON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- THR-B Agonists
- GLP-1 Receptor Agonists
- Antifibrotic Agents
- FXR Agonists
- Lipid-Lowering Agents
- Thiazolidinediones
- Antioxidants
- Others
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Parenteral
- Oral
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2020 - 2033
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY AGE GROUP- MARKET ANALYSIS, 2020 - 2033
- Geriatric
- Adults
- Pediatric
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Table of Contents
1. Non-Alcoholic Fatty Liver Disease Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.2. Competitive Insights
3. Non-Alcoholic Fatty Liver Disease Key Market Trends
- 3.1. Non-Alcoholic Fatty Liver Disease Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Non-Alcoholic Fatty Liver Disease Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Non-Alcoholic Fatty Liver Disease Market Opportunities
- 3.4. Non-Alcoholic Fatty Liver Disease Market Future Trends
4. Non-Alcoholic Fatty Liver Disease Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Non-Alcoholic Fatty Liver Disease Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Non-Alcoholic Fatty Liver Disease Market Landscape
- 6.1. Non-Alcoholic Fatty Liver Disease Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Non-Alcoholic Fatty Liver Disease Market - By Drug Class
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
- 7.1.2. THR-B Agonists
- 7.1.3. GLP-1 Receptor Agonists
- 7.1.4. Antifibrotic Agents
- 7.1.5. FXR Agonists
- 7.1.6. Lipid-Lowering Agents
- 7.1.7. Thiazolidinediones
- 7.1.8. Antioxidants
- 7.1.9. Others
8. Non-Alcoholic Fatty Liver Disease Market - By Route of Administration
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 8.1.2. Parenteral
- 8.1.3. Oral
9. Non-Alcoholic Fatty Liver Disease Market - By Distribution
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution, 2025 & 2033 (%)
- 9.1.2. Retail Pharmacies
- 9.1.3. Hospital Pharmacies
- 9.1.4. Online Pharmacies
- 9.1.5. Others
10. Non-Alcoholic Fatty Liver Disease Market - By Age Group
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Age Group, 2025 & 2033 (%)
- 10.1.2. Geriatric
- 10.1.3. Adults
- 10.1.4. Pediatric
11. Non-Alcoholic Fatty Liver Disease Market- By Geography
- 11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 11.2. North America
- 11.2.1. Overview
- 11.2.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.2.8. U.S.
- 11.2.8.1. Overview
- 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.2.8.6. U.S. Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.2.9. Canada
- 11.2.9.1. Overview
- 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.2.9.6. Canada Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3. Europe
- 11.3.1. Overview
- 11.3.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.8. Germany
- 11.3.8.1. Overview
- 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.8.6. Germany Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.9. UK
- 11.3.9.1. Overview
- 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.9.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.9.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.9.5. UK Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.9.6. UK Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.10. France
- 11.3.10.1. Overview
- 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.10.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.10.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.10.5. France Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.10.6. France Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.11. Italy
- 11.3.11.1. Overview
- 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.11.5. Italy Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.11.6. Italy Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.12. Spain
- 11.3.12.1. Overview
- 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.12.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.12.5. Spain Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.12.6. Spain Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.13. The Netherlands
- 11.3.13.1. Overview
- 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.13.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.13.6. The Netherlands Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.14. Sweden
- 11.3.14.1. Overview
- 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.14.6. Sweden Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.15. Russia
- 11.3.15.1. Overview
- 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.15.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.15.5. Russia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.15.6. Russia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.16. Poland
- 11.3.16.1. Overview
- 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.16.5. Poland Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.16.6. Poland Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.17. Denmark
- 11.3.17.1. Overview
- 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.17.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.17.5. Denmark Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.17.6. Denmark Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.3.18. Rest of Europe
- 11.3.18.1. Overview
- 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.3.18.6. Rest of the Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.8. China
- 11.4.8.1. Overview
- 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.8.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.8.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.8.5. China Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.8.6. China Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.9. India
- 11.4.9.1. Overview
- 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.9.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.9.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.9.5. India Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.9.6. India Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.10. Japan
- 11.4.10.1. Overview
- 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.10.6. Japan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.11. South Korea
- 11.4.11.1. Overview
- 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.11.6. South Korea Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.12. Australia
- 11.4.12.1. Overview
- 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.12.6. Australia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.13. Indonesia
- 11.4.13.1. Overview
- 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.13.6. Indonesia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.14. Thailand
- 11.4.14.1. Overview
- 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.14.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.14.5. Thailand Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.14.6. Thailand Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.15. Philippines
- 11.4.15.1. Overview
- 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.15.6. Philippines Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.16. Taiwan
- 11.4.16.1. Overview
- 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.16.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.16.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.16.5. Taiwan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.16.6. Taiwan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.17. Vietnam
- 11.4.17.1. Overview
- 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.17.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.17.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.17.5. Vietnam Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.17.6. Vietnam Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.4.18. Rest of APAC
- 11.4.18.1. Overview
- 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.18.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.18.5. Rest of APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.4.18.6. Rest of APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.5.8. Brazil
- 11.5.8.1. Overview
- 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.5.8.6. Brazil Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.5.9. Mexico
- 11.5.9.1. Overview
- 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.5.9.6. Mexico Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.5.10. Argentina
- 11.5.10.1. Overview
- 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.5.10.6. Argentina Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.5.11. Colombia
- 11.5.11.1. Overview
- 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.5.11.6. Colombia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.5.12. Rest of LATAM
- 11.5.12.1. Overview
- 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.5.12.6. Rest of LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.8. Saudi Arabia
- 11.6.8.1. Overview
- 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.8.6. Saudi Arabia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.9. United Arab Emirates
- 11.6.9.1. Overview
- 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.9.6. United Arab Emirates Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.10. Israel
- 11.6.10.1. Overview
- 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.10.6. Israel Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.11. Turkey
- 11.6.11.1. Overview
- 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.11.6. Turkey Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.12. Algeria
- 11.6.12.1. Overview
- 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.12.6. Algeria Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.13. Egypt
- 11.6.13.1. Overview
- 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.13.6. Egypt Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.14. Iran
- 11.6.14.1. Overview
- 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.14.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.14.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.14.5. Iran Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.14.6. Iran Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.15. Qatar
- 11.6.15.1. Overview
- 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.15.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.15.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.15.5. Qatar Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.15.6. Qatar Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 11.6.16. Rest of MEA
- 11.6.16.1. Overview
- 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.16.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.16.5. Rest of MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 11.6.16.6. Rest of MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Non-Alcoholic Fatty Liver Disease Industry
- 12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
- 12.2. Company Profiles
- 12.2.1. Madrigal Pharmaceuticals, Inc.
- 12.2.2. Novo Nordisk A/S
- 12.2.3. Eli Lilly and Company
- 12.2.4. F. Hoffmann-La Roche Ltd. / 89bio
- 12.2.5. Gilead Sciences, Inc.
- 12.2.6. AbbVie Inc.
- 12.2.7. Pfizer Inc.
- 12.2.8. Boehringer Ingelheim International GmbH
- 12.2.9. Inventiva S.A.
- 12.2.10. AstraZeneca plc
- 12.2.11. GSK plc
- 12.2.12. Viking Therapeutics, Inc.
- 12.2.13. Altimmune, Inc.
- 12.2.14. Sagimet Biosciences Inc.
- 12.2.15. Terns Pharmaceuticals, Inc.
- 12.2.16. Galectin Therapeutics Inc.
- 12.2.17. Galmed Pharmaceuticals Ltd.
- 12.2.18. NGM Biopharmaceuticals, Inc.
- 12.2.19. Bristol Myers Squibb
- 12.2.20. Zydus Lifesciences Ltd.
- 12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
- 14.1. Research Methodology
- 14.2. References
- 14.3. Abbreviations
- 14.4. Disclaimer
- 14.5. Contact Us
